Biobran / MGN-3 / Arabinoxylan Rice Bran

Overview

This video features Dr. Fabrice Andre presenting on translational breast cancer research, specifically addressing the role of growth factor receptors and targeted therapies. He emphasizes the importance of recognizing that each breast cancer patient is unique, with distinct molecular drivers of oncogenesis. The presentation highlights efforts to identify these key pathways in individual patients to enable personalized treatment strategies.

Dr. Andre explains that advances in technology, such as whole genome arrays, allow researchers to pinpoint the molecular abnormalities responsible for cancer in approximately 20 to 30% of patients. This identification can guide the selection of specific drugs tailored to the patient's tumor biology.

However, he also discusses the challenges of integrating these large-scale molecular analyses into routine clinical practice. These challenges include ensuring technological quality control and designing clinical trials that accommodate individualized treatment approaches. The meeting where Dr. Andre spoke brought together experts from research, technology, and clinical fields to foster collaboration and accelerate the translation of scientific advances into daily medical practice.

Source Information

This content is derived from a 2-minute and 14-second video interview with Dr. Fabrice Andre, MD, PhD, recorded at the IMPAKT 2009 conference in Brussels. The video is hosted on Vimeo and is part of ecancer's collection on cancer-related research and treatment topics. The transcript provided forms the basis of this summary, reflecting Dr. Andre's insights on targeted therapy and individualized treatment in breast cancer research.

Overview

In this video, Dr. Fabrice Andre explains the rationale, design, and results of the SAFIR02-BREAST randomized trial, which evaluated the clinical utility of molecular tumour profiling in metastatic breast cancer. The study focused on whether identifying oncogenic mutations through multigene sequencing and treating patients with targeted therapies matched to these genomic alterations could improve outcomes compared to standard maintenance chemotherapy.

Study Background and Design

Dr. Andre begins by noting that many breast cancers harbor oncogenic mutations that can sometimes be effectively targeted by specific drugs. The key question addressed was whether comprehensive detection of these mutations in each patient via multigene sequencing would translate into better clinical outcomes.

The trial enrolled patients with metastatic breast cancer who had received no more than one prior chemotherapy line and did not have HER2 overexpression. Genomic profiling was performed on tumor tissue or blood samples to identify actionable genomic alterations.

Patients who showed disease control after six to eight cycles of chemotherapy and had targetable genomic alterations were randomized to receive either one of nine targeted therapies matched to their specific genomic alteration or to continue maintenance chemotherapy.

Primary Objectives and Results

• First objective: To determine if targeted therapy matched to genomic alterations ranked level one or two (according to the ESMO scale) improved progression-free survival (PFS) in patients with actionable mutations. Among 115 patients with such alterations, targeted therapy significantly improved PFS from 2 months to 9 months, with a hazard ratio of 0.41.
• Second objective: To assess if targeted therapy improved outcomes in the intent-to-treat population with any actionable alteration. This group showed a smaller PFS improvement of 2 months, which did not reach statistical significance (p=0.10).

Thus, the trial met its first primary objective, demonstrating that targeted therapies matched to high-level actionable genomic alterations can improve patient outcomes.

Clinical Implications

Dr. Andre highlights two key impacts of these findings on clinical practice:

• It is becoming mandatory to include a ranking of genomic alterations in genomic reports to guide treatment decisions effectively.
• Patients benefit from access to multigene sequencing technology, which should be made widely available to identify actionable mutations and enable personalized therapy.

He emphasizes the importance of providing oncologists with interpretable genomic reports that include the level of evidence for each alteration to facilitate optimal treatment selection.

Source Information

This content is based on a video interview with Dr. Fabrice Andre published by ecancer, discussing the SAFIR02-BREAST trial and the clinical utility of molecular tumour profiling in breast cancer. The video is available on Vimeo and was recorded in December 2021.

The remarkable story of Royal Rife, inventor, designer, researcher. Royal Rife designed and built the most magnificent microscope ever! He also was involved in creating what became known as the 'RIFE MACHINE' which was manufactured for a short while under different names. Most remarkable however was he discoveries of destroying virus's, including cancer, using his non-invasive 'RIFE MACHINE'. But, as is the case so often, a great discovery and invention is stopped, because of greed, fear, ignorance and avarice, as was the case here.

This amazing documentary will make you think again when you hear that there is 'no cure' for cancer and other diseases. And this story is not the only one.